Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for transplant patients: study aims to stop hidden virus after standard treatment ends

NCT ID NCT06958796

First seen Nov 03, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This study tests whether giving an extra drug called CytoGam® after standard antiviral treatment can help prevent late CMV infection in people who received a kidney or liver transplant. About 80 high-risk patients (where the donor had CMV but the recipient did not) will take part. The goal is to see if this approach reduces the chance of getting sick from CMV after the usual preventive medicines are stopped.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT; COMPLICATIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Texas Southwestern

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.